L. De-lau and M. Breteler, Epidemiology of Parkinson's disease, The Lancet Neurology, vol.5, issue.6, pp.525-535, 2006.
DOI : 10.1016/S1474-4422(06)70471-9

G. Cotzias, P. Papavasiliou, and R. Gellene, Modification of Parkinsonism ??? Chronic Treatment with L-Dopa, New England Journal of Medicine, vol.280, issue.7, pp.337-345, 1969.
DOI : 10.1056/NEJM196902132800701

C. Marsden, Parkinson's disease., Journal of Neurology, Neurosurgery & Psychiatry, vol.57, issue.6, pp.672-681, 1994.
DOI : 10.1136/jnnp.57.6.672

T. Chase, Levodopa therapy: Consequences of the nonphysiologic replacement of dopamine, Neurology, vol.50, issue.Issue 5, Supplement 5, pp.17-25, 1998.
DOI : 10.1212/WNL.50.5_Suppl_5.S17

O. Rascol and N. Fabre, Dyskinesia: L-Dopa-Induced and Tardive Dyskinesia, Clinical Neuropharmacology, vol.24, issue.6, pp.313-323, 2001.
DOI : 10.1097/00002826-200111000-00002

R. Burns, C. Chiueh, S. Markey, M. Ebert, and D. Jacobowitz, A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine., Proceedings of the National Academy of Sciences, vol.80, issue.14, pp.6-4546, 1983.
DOI : 10.1073/pnas.80.14.4546

J. Langston, E. Langston, and I. Irwin, MPTP-induced parkinsonism in human and non-human primates-clinical and experimental aspects, Acta Neurol Scand, vol.100, pp.49-54, 1984.

P. Hantraye, M. Varastet, M. Peschanski, D. Riche, and P. Cesaro, Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons, Neuroscience, vol.53, issue.1, pp.169-178, 1993.
DOI : 10.1016/0306-4522(93)90295-Q

M. Varastet, D. Riche, M. Maziere, and P. Hantraye, Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in parkinson's disease, Neuroscience, vol.63, issue.1, pp.47-56, 1994.
DOI : 10.1016/0306-4522(94)90006-X

E. Bezard, . Ds, B. Bioulac, and C. Gross, Kinetics of nigral degeneration in a chronic model of MPTP-treated mice, Neuroscience Letters, vol.234, issue.1, p.3, 1997.
DOI : 10.1016/S0304-3940(97)00663-0

E. Bezard, C. Imbert, and C. Gross, Experimental Models of Parkinson's Disease: From the Static to the Dynamic, Reviews in the Neurosciences, vol.9, issue.2, pp.71-90, 1998.
DOI : 10.1515/REVNEURO.1998.9.2.71

N. Schmidt and B. Ferger, Neurochemical findings in the MPTP model of Parkinson's disease, Journal of Neural Transmission, vol.108, issue.11, pp.1263-1282, 2001.
DOI : 10.1007/s007020100004

P. Blanchet, F. Calon, M. Morissette, H. Tahar, A. Bélanger et al., Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms, Parkinsonism & Related Disorders, vol.10, issue.5, pp.297-304, 2004.
DOI : 10.1016/j.parkreldis.2004.02.011

P. Bédard, P. Blanchet, D. Lévesque, J. Soghomonian, and R. Grondin, Pathophysiology of L-dopa-induced dyskinesias, Mov Disord, vol.14, issue.1, pp.4-8, 1999.

H. Tahar, A. Grondin, R. Grégoire, L. Calon, F. et al., New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable, Adv Neurol, vol.91, pp.51-64, 2003.

P. Chabrier and M. Auguet, Pharmacological Properties of BN82451: A Novel Multitargeting Neuroprotective Agent, CNS Drug Reviews, vol.111, issue.2, pp.317-332, 2007.
DOI : 10.1002/ana.10476

B. Spinnewyn, G. Mautino, J. Marin, M. Rocher, and A. Grandoulier, BN82451 attenuates l-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson???s disease, Neuropharmacology, vol.60, issue.4, pp.692-700, 2011.
DOI : 10.1016/j.neuropharm.2010.11.019

D. Dotto, P. Pavese, N. Gambaccini, G. Bernardini, S. Metman et al., Intravenous amantadine improves levodopa-induced dyskinesias: an acute double-blind placebo controlled study Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized , double-blind, placebo-controlled study, Mov Disord Parkinsonism Relat Disord, vol.16, issue.11, pp.515-520, 2001.

H. Sawada, T. Oeda, S. Kuno, M. Nomoto, and K. Yamamoto, Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial, PLoS ONE, vol.77, issue.12, p.15298, 2010.
DOI : 10.1371/journal.pone.0015298.s005

E. Wolf, K. Seppi, R. Katzenschlager, G. Hochschorner, and G. Ransmayr, Long-term antidyskinetic efficacy of amantadine in Parkinson's disease, Movement Disorders, vol.27, issue.10, pp.1357-1363, 2010.
DOI : 10.1002/mds.23034

J. Church, D. Martz, and N. Cook, The use of digital video recorders (DVRs) for capturing digital video files for use in both The Observer and Ethovision, Behavior Research Methods, vol.38, issue.3, pp.434-438, 2006.
DOI : 10.3758/BF03192797

A. Walton, A. Branham, D. Gash, and R. Grondin, Automated video analysis of age-related motor deficits in monkeys using EthoVision, Neurobiology of Aging, vol.27, issue.10, pp.1477-1483, 2006.
DOI : 10.1016/j.neurobiolaging.2005.08.003

B. Jarraya, S. Boulet, G. Ralph, C. Jan, and G. Bonvento, Dopamine Gene Therapy for Parkinson's Disease in a Nonhuman Primate Without Associated Dyskinesia, Science Translational Medicine, vol.1, issue.2, pp.2-4, 2009.
DOI : 10.1126/scitranslmed.3000130

S. Papa and T. Chase, Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonia monkeys, Annals of Neurology, vol.343, issue.5, pp.574-578, 1996.
DOI : 10.1002/ana.410390505

J. Obeso, C. Olanow, and J. Nutt, Levodopa motor complications in Parkinson's disease, Trends in Neurosciences, vol.23, pp.2-7, 2000.
DOI : 10.1016/S1471-1931(00)00031-8

M. Shin, C. Jan, C. Jacquard, B. Jarraya, and J. Callebert, Chronic systemic treatment with a high-dose proteasome inhibitor in mice produces akinesia unrelated to nigrostriatal degeneration, Neurobiology of Aging, vol.32, issue.11, pp.2100-2102, 2011.
DOI : 10.1016/j.neurobiolaging.2009.11.015

C. Patlak and R. Blasberg, Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations, Journal of Cerebral Blood Flow & Metabolism, vol.226, issue.4, pp.584-590, 1985.
DOI : 10.1038/jcbfm.1985.87

T. Poyot, F. Condé, M. Grégoire, V. Frouin, and C. Coulon, Anatomic and Biochemical Correlates of the Dopamine Transporter Ligand 11C-PE2I in Normal and Parkinsonian Primates: Comparison With 6-[18F]Fluoro-L-Dopa, Journal of Cerebral Blood Flow & Metabolism, vol.13, 2001.
DOI : 10.1097/00004647-200107000-00003

P. Blanchet, S. Konitsiotis, and T. Chase, Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys, Movement Disorders, vol.602, issue.5, pp.798-802, 1998.
DOI : 10.1002/mds.870130507

M. Hill, P. Ravenscroft, E. Bezard, A. Crossman, and J. Brotchie, Levetiracetam Potentiates the Antidyskinetic Action of Amantadine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson's Disease, Journal of Pharmacology and Experimental Therapeutics, vol.310, issue.1, pp.386-394, 2004.
DOI : 10.1124/jpet.104.066191

F. Bibbiani, J. Oh, A. Kielaite, M. Collins, and C. Smith, Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD, Experimental Neurology, vol.196, issue.2, pp.422-429, 2005.
DOI : 10.1016/j.expneurol.2005.08.017

C. Kobylecki, M. Hill, A. Crossman, and P. Ravenscroft, Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease, Movement Disorders, vol.64, issue.Suppl 1, pp.2354-2363, 2001.
DOI : 10.1002/mds.23867

J. Koprich, S. Fox, T. Johnston, A. Goodman, L. Bourdonnec et al., The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease, Movement Disorders, vol.19, issue.4 Suppl 1, pp.1225-1233, 2011.
DOI : 10.1002/mds.23631

J. Schneider, A. Pope-coleman, M. Van-velson, F. Menzaghi, and G. Lloyd, Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys, Movement Disorders, vol.547, issue.4, pp.637-642, 1998.
DOI : 10.1002/mds.870130405

M. Iravani, M. Jackson, M. Kuoppamä-ki, L. Smith, and P. Jenner, 4- methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated primates, J Neurosci, vol.3, issue.23, pp.9107-9115, 2003.

C. Konradi, J. Westin, M. Carta, M. Eaton, and K. Kuter, Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia, Neurobiology of Disease, vol.17, issue.2, pp.219-236, 2004.
DOI : 10.1016/j.nbd.2004.07.005

V. Sgambato-faure, V. Buggia, F. Gilbert, D. Lévesque, and A. Benabid, Coordinated and Spatial Upregulation of Arc in Striatonigral Neurons Correlates With L-Dopa-Induced Behavioral Sensitization in Dyskinetic Rats, Journal of Neuropathology and Experimental Neurology, vol.64, issue.11, pp.936-947, 2005.
DOI : 10.1097/01.jnen.0000186922.42592.b7
URL : https://hal.archives-ouvertes.fr/inserm-00391107

C. Bramham, M. Alme, M. Bittins, S. Kuipers, and R. Nair, The Arc of synaptic memory, Experimental Brain Research, vol.2, issue.5, pp.125-140, 2010.
DOI : 10.1007/s00221-009-1959-2

F. Huang, J. Chotiner, and O. Steward, Actin Polymerization and ERK Phosphorylation Are Required for Arc/Arg3.1 mRNA Targeting to Activated Synaptic Sites on Dendrites, Journal of Neuroscience, vol.27, issue.34, pp.9054-9067, 2007.
DOI : 10.1523/JNEUROSCI.2410-07.2007

O. Steward and P. Worley, Selective Targeting of Newly Synthesized Arc mRNA to Active Synapses Requires NMDA Receptor Activation, Neuron, vol.30, issue.1, pp.227-240, 2001.
DOI : 10.1016/S0896-6273(01)00275-6

P. Calabresi, P. Giacomini, D. Centonze, and G. Bernardi, Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?, Ann Neurol, vol.47, pp.60-68, 2000.

T. Chase and J. Oh, Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications, Ann Neurol, vol.47, pp.122-130, 2000.

V. Sgambato-faure and M. Cenci, Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease, Progress in Neurobiology, vol.96, issue.1, pp.69-86, 2012.
DOI : 10.1016/j.pneurobio.2011.10.005

P. Castillo, A. Francesconi, and R. Carroll, The Ups and Downs of Translation-Dependent Plasticity, Neuron, vol.59, issue.1, pp.1-3, 2008.
DOI : 10.1016/j.neuron.2008.06.016